Compare Stocks: EKTAY, BNR, CDNA, VCYT, and NVTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$9.22 -2.4%	$9.56	$6.79 ▼ $41.72	$99.40M	1.38	7,359 shs	3,387 shs
CDNA CareDx	$48.97 -2.3%	$39.39	$12.37 ▼ $53.67	$2.59B	2.38	1.11 million shs	1.25 million shs
EKTAY Elekta	$5.48 -2.1%	$5.23	$4.35 ▼ $6.93	$2.06B	1.05	2,958 shs	560 shs
NVTA Invitae	$0.00	$0.00	$0.02 ▼ $0.02	$80K	1.59	23.72 million shs	N/A
VCYT Veracyte	$43.43 +0.6%	$51.51	$29.38 ▼ $60.91	$3.47B	1.93	1.29 million shs	872,988 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-7.26%	-4.68%	+7.51%	-1.97%	+10.47%
CDNA CareDx	+0.64%	+5.49%	+14.64%	+127.05%	+266.84%
EKTAY Elekta	-0.53%	-3.51%	+10.91%	-2.69%	+13.71%
NVTA Invitae	0.00%	0.00%	0.00%	0.00%	0.00%
VCYT Veracyte	-0.35%	+4.15%	-6.76%	-9.64%	+42.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$9.22 -2.4%	$9.56	$6.79 ▼ $41.72	$99.40M	1.38	7,359 shs	3,387 shs
CDNA CareDx	$48.97 -2.3%	$39.39	$12.37 ▼ $53.67	$2.59B	2.38	1.11 million shs	1.25 million shs
EKTAY Elekta	$5.48 -2.1%	$5.23	$4.35 ▼ $6.93	$2.06B	1.05	2,958 shs	560 shs
NVTA Invitae	$0.00	$0.00	$0.02 ▼ $0.02	$80K	1.59	23.72 million shs	N/A
VCYT Veracyte	$43.43 +0.6%	$51.51	$29.38 ▼ $60.91	$3.47B	1.93	1.29 million shs	872,988 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	-7.26%	-4.68%	+7.51%	-1.97%	+10.47%
CDNA CareDx	+0.64%	+5.49%	+14.64%	+127.05%	+266.84%
EKTAY Elekta	-0.53%	-3.51%	+10.91%	-2.69%	+13.71%
NVTA Invitae	0.00%	0.00%	0.00%	0.00%	0.00%
VCYT Veracyte	-0.35%	+4.15%	-6.76%	-9.64%	+42.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
CDNA CareDx	2.57	Moderate Buy	$47.75	-2.49% Downside
EKTAY Elekta	1.50	Reduce	N/A	N/A
NVTA Invitae	0.00	N/A	N/A	N/A
VCYT Veracyte	2.82	Moderate Buy	$54.33	25.11% Upside

Current Analyst Ratings Breakdown

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	CDNA CareDx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/11/2026	VCYT Veracyte	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/7/2026	VCYT Veracyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/6/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	CDNA CareDx	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $60.00
8/4/2026	VCYT Veracyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$66.00 ➝ $54.00
8/4/2026	VCYT Veracyte	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$68.00 ➝ $55.00
8/4/2026	VCYT Veracyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Underweight	$47.00 ➝ $44.00

(Data available from 9/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.26	N/A	N/A	$7.28 per share	1.27
CDNA CareDx	$458.09M	5.53	$0.01 per share	7,693.37	$8.23 per share	5.95
EKTAY Elekta	$1.78B	1.13	$0.62 per share	8.91	$2.07 per share	2.65
NVTA Invitae	$481.58M	0.00	N/A	N/A	$0.42 per share	0.00
VCYT Veracyte	$517.15M	6.75	$1.50 per share	29.00	$17.27 per share	2.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.82	N/A	N/A	N/A	-11.57%	-10.98%	-7.33%	9/2/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	23.66	77.73	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
EKTAY Elekta	-$55.38M	-$0.12	N/A	11.66	N/A	-2.38%	13.31%	3.80%	N/A
NVTA Invitae	-$3.11B	-$5.38	N/A	N/A	N/A	-299.14%	-6,100.71%	-19.68%	N/A
VCYT Veracyte	$66.35M	$1.41	30.80	28.20	N/A	20.37%	9.26%	8.61%	11/3/2026 (Estimated)

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	N/A	N/A	N/A	$19.21 million	N/A
8/27/2026	Q1 2027	EKTAY Elekta	N/A	$0.07	N/A	$0.07	N/A	$372.30 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million
7/30/2026	Q2 2026	VCYT Veracyte	$0.4103	$0.54	+$0.1297	$0.31	$144.59 million	$150.32 million
6/9/2026	Q1 2026	BNR Burning Rock Biotech	-$2.2884	-$0.20	+$2.0884	-$0.25	$19.21 million	$15.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
EKTAY Elekta	$0.13	2.37%	N/A	N/A	N/A
NVTA Invitae	N/A	N/A	N/A	N/A	N/A
VCYT Veracyte	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	0.06	3.05	2.81
CDNA CareDx	N/A	4.58	4.51
EKTAY Elekta	0.47	0.87	0.68
NVTA Invitae	N/A	2.39	2.25
VCYT Veracyte	N/A	9.16	8.80

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
CDNA CareDx	N/A
EKTAY Elekta	N/A
NVTA Invitae	61.28%
VCYT Veracyte	N/A

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
CDNA CareDx	2.40%
EKTAY Elekta	41.28%
NVTA Invitae	0.74%
VCYT Veracyte	1.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	1,390	10.52 million	7.33 million	Not Optionable
CDNA CareDx	740	51.73 million	50.49 million	Optionable
EKTAY Elekta	4,556	368.59 million	216.44 million	Not Optionable
NVTA Invitae	1,700	267.01 million	284.37 million	No Data
VCYT Veracyte	790	80.39 million	79.11 million	Optionable

EKTAY, BNR, CDNA, VCYT, and NVTA Headlines

Recent News About These Companies

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 1 at 4:05 PM | globenewswire.com

Veracyte, Inc. $VCYT Shares Sold by Moore Capital Management LP

September 1 at 5:44 AM | marketbeat.com

Wellington Management Group LLP Lowers Position in Veracyte, Inc. $VCYT

September 1 at 5:12 AM | marketbeat.com

161,973 Shares in Veracyte, Inc. $VCYT Bought by Corient Private Wealth LP

August 31 at 3:44 AM | marketbeat.com

Alyeska Investment Group L.P. Lowers Stock Position in Veracyte, Inc. $VCYT

August 31 at 3:04 AM | marketbeat.com

269,806 Shares in Veracyte, Inc. $VCYT Purchased by Jupiter Topco LLC

August 30 at 5:04 AM | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT

August 30 at 3:37 AM | marketbeat.com

437,604 Shares in Veracyte, Inc. $VCYT Purchased by Bank of New York Mellon Corp

August 30 at 3:20 AM | marketbeat.com

Legal & General Group Plc Invests $50.40 Million in Veracyte, Inc. $VCYT

August 29 at 5:35 AM | marketbeat.com

Formula Growth Ltd. Purchases Shares of 27,000 Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

Analyzing Wesana Health (OTCMKTS:WSNAF) & Veracyte (NASDAQ:VCYT)

August 28, 2026 | americanbankingnews.com

Freestone Grove Partners LP Makes New Investment in Veracyte, Inc. $VCYT

August 28, 2026 | marketbeat.com

Veracyte, Inc. (VCYT) Stock Price, News, Quote & History - Yahoo Finance

August 28, 2026 | finance.yahoo.com

50,484 Shares in Veracyte, Inc. $VCYT Bought by Cibc World Market Inc.

August 27, 2026 | marketbeat.com

Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYT

August 27, 2026 | marketbeat.com

Veracyte (VCYT) Receives a Buy from Piper Sandler

August 26, 2026 | theglobeandmail.com

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

August 26, 2026 | zacks.com

123,015 Shares in Veracyte, Inc. $VCYT Acquired by EFG International AG

August 26, 2026 | marketbeat.com

Castleark Management LLC Buys New Position in Veracyte, Inc. $VCYT

August 26, 2026 | marketbeat.com

VCYT Drops 25.3% in the Past Month. Is the Sell-Off an Opportunity?

August 25, 2026 | zacks.com

Deutsche Bank AG Buys New Shares in Veracyte, Inc. $VCYT

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKTAY, BNR, CDNA, VCYT, and NVTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$9.22 -0.23 (-2.43%)

As of 03:00 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

CareDx NASDAQ:CDNA

$48.97 -1.14 (-2.27%)

As of 04:00 PM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Elekta OTCMKTS:EKTAY

$5.48 -0.12 (-2.14%)

As of 11:06 AM Eastern

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Veracyte NASDAQ:VCYT

$43.43 +0.24 (+0.56%)

As of 04:00 PM Eastern

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EKTAY, BNR, CDNA, VCYT, and NVTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKTAY, BNR, CDNA, VCYT, and NVTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

CareDx NASDAQ:CDNA

Elekta OTCMKTS:EKTAY

Invitae NYSE:NVTA

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EKTAY, BNR, CDNA, VCYT, and NVTA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EKTAY, BNR, CDNA, VCYT, and NVTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

EKTAY, BNR, CDNA, VCYT, and NVTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

CareDx NASDAQ:CDNA

Elekta OTCMKTS:EKTAY

Invitae NYSE:NVTA

Veracyte NASDAQ:VCYT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools